Evaluation of regorafenib in colorectal cancer and GIST

Mené sur 240 patients atteints d'une tumeur stromale gastro-intestinale métastatique ou non résécable ayant progressé après l'échec d'un traitement par imatinib et sunitinib (57 centres hospitaliers, 17 pays), cet essai international de phase III évalue le regorafenib du point de vue de la survie sans progression

Résumé en anglais

Regorafenib is an orally administered multikinase inhibitor. It is administered on a continuous dosing schedule and shows non-specific binding to several intracellular kinases, with potent inhibitory activity against vascular endothelial growth factor receptors 1—3 (VEGFR1 [also known as FLT1 ] , VEGFR2 [KDR ] , and VEGFR3 [FLT4 ] ), PDGFRB, FGFR1, RAF, TIE2, and the mutant oncogenic kinases KIT, RET, and BRAF. Commonly reported ( > 10%) toxic effects include fatigue, hand-foot skin reaction, diarrhoea, ...